Together, these indicated that silencing Fbxo45 played additive effects with Afatinib on suppressing the tumor growth of H1975 cells, even though harboring EGFR‐T790M resistance mutation and KRAS mutation, in vitro and in vivo. Here, KRAS is linked to neoplasm.